Paediatric Neuro-oncology
Research activity is centred on newly diagnosed high grade glioma, including diffuse intrinsic pontine glioma, with a focus on children treated through the KiTZ Clinical Trial Group in Columbus.
- High grade glioma
- Diffuse intrinsic pontine glioma
- Paediatric brain tumours
The clinical research landscape is concentrated on aggressive central nervous system malignancies in young children, with active collaboration across multiple research sites in the United States.
Molecularly Defined Tumours
The sponsor’s trial activity includes NTRK fusion-positive disease, reflecting interest in genetically defined childhood cancers and their treatment implications.
- NTRK fusion-associated tumours
- Precision oncology
- Targeted cancer therapy
This area links tumour biology with treatment selection in paediatric neuro-oncology, particularly for children whose tumours carry actionable molecular alterations.
Targeted Therapy in Childhood Cancer
Clinical interest extends to larotrectinib as a targeted treatment for young children with NTRK fusion-driven high grade glioma, supporting research in molecularly guided oncology care.
- Larotrectinib
- Oncogenic fusion targets
- Childhood cancer therapeutics
The funded research examines treatment activity in relation to tumour response and disease control within paediatric brain cancer.
Combination and Post-radiation Treatment Strategies
Additional research attention is directed toward the use of targeted therapy alongside chemotherapy and after focal radiation therapy in children with high grade glioma.
- Chemotherapy combinations
- Post-radiation therapy
- Integrated paediatric cancer treatment
These interests place emphasis on treatment feasibility and safety in the setting of complex multimodal care for paediatric brain tumours.
